PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette E Latchman, Clive R. Wood, Tatyana Chernova et al. · Nature Immunology · 2001
Cited by 2,952 works. doi:10.1038/85330
Authors
- Yvette E Latchman
- Clive R. Wood
- Tatyana Chernova
- Divya Chaudhary
- Madhuri Borde
- Irene Chernova
- Yoshiko Iwai
- Andrew J. Long
- Julia A. Brown
- Raquel Nunes
- Edward A. Greenfield
- Karen Bourque
- Vassiliki A. Boussiotis
- Laura Carter
- Beatriz M. Carreno
- Nelly Malenkovich
- Hiroyuki Nishimura
- Taku Okazaki
- Tasuku Honjo
- Arlene H. Sharpe
References
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
- CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
- CTLA-4 ligation blocks CD28-dependent T cell activation.